Cargando…

Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis

Heterotopic ossification (HO) is a frequent complication after total hip arthroplasty (THA). Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used as routine prophylaxis for HO after THA. However, the efficacy of NSAIDs on HO, particularly selective NSAIDs versus nonselective NSAIDs, is uncer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kan, Shun-Li, Yang, Bo, Ning, Guang-Zhi, Chen, Ling-Xiao, Li, Yu-Lin, Gao, Shi-Jie, Chen, Xing-Yu, Sun, Jing-Cheng, Feng, Shi-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602535/
https://www.ncbi.nlm.nih.gov/pubmed/25950691
http://dx.doi.org/10.1097/MD.0000000000000828
_version_ 1782394740057047040
author Kan, Shun-Li
Yang, Bo
Ning, Guang-Zhi
Chen, Ling-Xiao
Li, Yu-Lin
Gao, Shi-Jie
Chen, Xing-Yu
Sun, Jing-Cheng
Feng, Shi-Qing
author_facet Kan, Shun-Li
Yang, Bo
Ning, Guang-Zhi
Chen, Ling-Xiao
Li, Yu-Lin
Gao, Shi-Jie
Chen, Xing-Yu
Sun, Jing-Cheng
Feng, Shi-Qing
author_sort Kan, Shun-Li
collection PubMed
description Heterotopic ossification (HO) is a frequent complication after total hip arthroplasty (THA). Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used as routine prophylaxis for HO after THA. However, the efficacy of NSAIDs on HO, particularly selective NSAIDs versus nonselective NSAIDs, is uncertain. We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov to identify randomized controlled trials with respect to HO after THA. Two reviewers extracted the data and estimated the risk of bias. For the ordered data, we followed the Bayesian framework to calculate the odds ratio (OR) with a 95% credible interval (CrI). For the dichotomous data, the OR and 95% confidence interval (CI) were calculated using Stata version 12.0. The subgroup analyses and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach were used. A total of 1856 articles were identified, and 21 studies (5995 patients) were included. In the NSAIDs versus placebo analysis, NSAIDs could decrease the incidence of HO, according to the Brooker scale (OR = 2.786, 95% CrI 1.879–3.993) and Delee scale (OR = 9.987, 95% CrI 5.592–16.17). In the selective NSAIDs versus nonselective NSAIDs analysis, there was no significant difference (OR = 0.7989, 95% CrI 0.5506–1.125) in the prevention of HO. NSAIDs could increase discontinuation caused by gastrointestinal side effects (DGSE) (OR = 1.28, 95% CI 1.00–1.63, P = 0.046) more than a placebo. Selective NSAIDs could decrease DGSE (OR = 0.48, 95% CI 0.24–0.97, P = 0.042) compared with the nonselective NSAIDs. There was no significant difference with respect to discontinuation caused by nongastrointestinal side effects (DNGSE) in NSAIDs versus a placebo (OR = 1.16, 95% CI 0.88–1.53, P = 0.297) and in selective NSAIDs versus nonselective NSAIDs (OR = 0.83, 95% CI 0.50–1.37, P = 0.462). NSAIDs might reduce the incidence of HO and increase DGSE in the short-term.
format Online
Article
Text
id pubmed-4602535
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46025352015-10-27 Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis Kan, Shun-Li Yang, Bo Ning, Guang-Zhi Chen, Ling-Xiao Li, Yu-Lin Gao, Shi-Jie Chen, Xing-Yu Sun, Jing-Cheng Feng, Shi-Qing Medicine (Baltimore) 7100 Heterotopic ossification (HO) is a frequent complication after total hip arthroplasty (THA). Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used as routine prophylaxis for HO after THA. However, the efficacy of NSAIDs on HO, particularly selective NSAIDs versus nonselective NSAIDs, is uncertain. We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov to identify randomized controlled trials with respect to HO after THA. Two reviewers extracted the data and estimated the risk of bias. For the ordered data, we followed the Bayesian framework to calculate the odds ratio (OR) with a 95% credible interval (CrI). For the dichotomous data, the OR and 95% confidence interval (CI) were calculated using Stata version 12.0. The subgroup analyses and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach were used. A total of 1856 articles were identified, and 21 studies (5995 patients) were included. In the NSAIDs versus placebo analysis, NSAIDs could decrease the incidence of HO, according to the Brooker scale (OR = 2.786, 95% CrI 1.879–3.993) and Delee scale (OR = 9.987, 95% CrI 5.592–16.17). In the selective NSAIDs versus nonselective NSAIDs analysis, there was no significant difference (OR = 0.7989, 95% CrI 0.5506–1.125) in the prevention of HO. NSAIDs could increase discontinuation caused by gastrointestinal side effects (DGSE) (OR = 1.28, 95% CI 1.00–1.63, P = 0.046) more than a placebo. Selective NSAIDs could decrease DGSE (OR = 0.48, 95% CI 0.24–0.97, P = 0.042) compared with the nonselective NSAIDs. There was no significant difference with respect to discontinuation caused by nongastrointestinal side effects (DNGSE) in NSAIDs versus a placebo (OR = 1.16, 95% CI 0.88–1.53, P = 0.297) and in selective NSAIDs versus nonselective NSAIDs (OR = 0.83, 95% CI 0.50–1.37, P = 0.462). NSAIDs might reduce the incidence of HO and increase DGSE in the short-term. Wolters Kluwer Health 2015-05-08 /pmc/articles/PMC4602535/ /pubmed/25950691 http://dx.doi.org/10.1097/MD.0000000000000828 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 7100
Kan, Shun-Li
Yang, Bo
Ning, Guang-Zhi
Chen, Ling-Xiao
Li, Yu-Lin
Gao, Shi-Jie
Chen, Xing-Yu
Sun, Jing-Cheng
Feng, Shi-Qing
Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
title Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
title_full Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
title_fullStr Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
title_full_unstemmed Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
title_short Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
title_sort nonsteroidal anti-inflammatory drugs as prophylaxis for heterotopic ossification after total hip arthroplasty: a systematic review and meta-analysis
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602535/
https://www.ncbi.nlm.nih.gov/pubmed/25950691
http://dx.doi.org/10.1097/MD.0000000000000828
work_keys_str_mv AT kanshunli nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT yangbo nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT ningguangzhi nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT chenlingxiao nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT liyulin nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT gaoshijie nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT chenxingyu nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT sunjingcheng nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis
AT fengshiqing nonsteroidalantiinflammatorydrugsasprophylaxisforheterotopicossificationaftertotalhiparthroplastyasystematicreviewandmetaanalysis